Emergency Medicineintracerebral haemorrhageneurocritical care
Recombinant Factor VIIa Fails to Improve Functional Outcomes in Hyperacute Intracerebral Haemorrhage Despite Reduced Bleeding: Results from the FASTEST Trial
By MedXY|Feb 17, 2026
The FASTEST trial demonstrated that while recombinant factor VIIa administered within two hours of intracerebral haemorrhage onset significantly reduced hematoma growth, it failed to improve functional outcomes at 180 days and increased the
